CN109593717A - A kind of stem cell serum-free culture medium - Google Patents
A kind of stem cell serum-free culture medium Download PDFInfo
- Publication number
- CN109593717A CN109593717A CN201811639110.7A CN201811639110A CN109593717A CN 109593717 A CN109593717 A CN 109593717A CN 201811639110 A CN201811639110 A CN 201811639110A CN 109593717 A CN109593717 A CN 109593717A
- Authority
- CN
- China
- Prior art keywords
- stem cell
- free culture
- serum
- culture medium
- basal medium
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 210000000130 stem cell Anatomy 0.000 title claims abstract description 56
- 239000004017 serum-free culture medium Substances 0.000 title claims description 23
- 239000007640 basal medium Substances 0.000 claims abstract description 23
- 210000004027 cell Anatomy 0.000 claims abstract description 16
- 238000000338 in vitro Methods 0.000 claims abstract description 14
- 239000000203 mixture Substances 0.000 claims abstract description 13
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims abstract description 12
- -1 5-15mg/L Chemical compound 0.000 claims abstract description 10
- 239000004615 ingredient Substances 0.000 claims abstract description 9
- 102000004127 Cytokines Human genes 0.000 claims abstract description 8
- 108090000695 Cytokines Proteins 0.000 claims abstract description 8
- 108010049976 Bone Morphogenetic Protein 5 Proteins 0.000 claims abstract description 6
- 102000004877 Insulin Human genes 0.000 claims abstract description 6
- 108090001061 Insulin Proteins 0.000 claims abstract description 6
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 claims abstract description 6
- 229930182816 L-glutamine Natural products 0.000 claims abstract description 6
- 239000003102 growth factor Substances 0.000 claims abstract description 6
- 210000003958 hematopoietic stem cell Anatomy 0.000 claims abstract description 6
- 229940125396 insulin Drugs 0.000 claims abstract description 6
- 239000000654 additive Substances 0.000 claims abstract description 5
- 230000000996 additive effect Effects 0.000 claims abstract description 5
- 239000002131 composite material Substances 0.000 claims abstract description 5
- 150000002632 lipids Chemical class 0.000 claims abstract description 5
- 102000002070 Transferrins Human genes 0.000 claims abstract description 4
- 108010015865 Transferrins Proteins 0.000 claims abstract description 4
- 102000008152 Bone Morphogenetic Protein 5 Human genes 0.000 claims abstract 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 claims description 17
- 102000004889 Interleukin-6 Human genes 0.000 claims description 16
- 108090001005 Interleukin-6 Proteins 0.000 claims description 16
- 229940100601 interleukin-6 Drugs 0.000 claims description 16
- 230000003321 amplification Effects 0.000 claims description 12
- 238000003199 nucleic acid amplification method Methods 0.000 claims description 12
- 210000003995 blood forming stem cell Anatomy 0.000 claims description 11
- 102000015696 Interleukins Human genes 0.000 claims description 7
- 108010063738 Interleukins Proteins 0.000 claims description 7
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 5
- 239000008103 glucose Substances 0.000 claims description 5
- 238000000034 method Methods 0.000 abstract description 8
- 230000000694 effects Effects 0.000 abstract description 6
- 210000002966 serum Anatomy 0.000 abstract description 6
- 239000000427 antigen Substances 0.000 abstract description 3
- 102000036639 antigens Human genes 0.000 abstract description 3
- 108091007433 antigens Proteins 0.000 abstract description 3
- 229940088597 hormone Drugs 0.000 abstract description 3
- 239000005556 hormone Substances 0.000 abstract description 3
- 230000035755 proliferation Effects 0.000 abstract description 3
- 239000000126 substance Substances 0.000 abstract description 3
- 230000004083 survival effect Effects 0.000 abstract description 3
- 102000000646 Interleukin-3 Human genes 0.000 description 8
- 108010002386 Interleukin-3 Proteins 0.000 description 8
- 229940076264 interleukin-3 Drugs 0.000 description 8
- 210000004369 blood Anatomy 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 102100022526 Bone morphogenetic protein 5 Human genes 0.000 description 4
- 238000012986 modification Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 230000000638 stimulation Effects 0.000 description 3
- 208000019838 Blood disease Diseases 0.000 description 2
- 208000027219 Deficiency disease Diseases 0.000 description 2
- 102000008857 Ferritin Human genes 0.000 description 2
- 108050000784 Ferritin Proteins 0.000 description 2
- 238000008416 Ferritin Methods 0.000 description 2
- 208000032843 Hemorrhage Diseases 0.000 description 2
- 208000026350 Inborn Genetic disease Diseases 0.000 description 2
- 206010035226 Plasma cell myeloma Diseases 0.000 description 2
- 208000007502 anemia Diseases 0.000 description 2
- 230000000740 bleeding effect Effects 0.000 description 2
- 208000016361 genetic disease Diseases 0.000 description 2
- 208000024908 graft versus host disease Diseases 0.000 description 2
- 230000003394 haemopoietic effect Effects 0.000 description 2
- 208000014951 hematologic disease Diseases 0.000 description 2
- 230000002607 hemopoietic effect Effects 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 208000032839 leukemia Diseases 0.000 description 2
- 201000000050 myeloid neoplasm Diseases 0.000 description 2
- 230000001613 neoplastic effect Effects 0.000 description 2
- 210000001113 umbilicus Anatomy 0.000 description 2
- 208000009329 Graft vs Host Disease Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000003694 hair properties Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 230000014599 transmission of virus Effects 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0647—Haematopoietic stem cells; Uncommitted or multipotent progenitors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/05—Inorganic components
- C12N2500/10—Metals; Metal chelators
- C12N2500/20—Transition metals
- C12N2500/24—Iron; Fe chelators; Transferrin
- C12N2500/25—Insulin-transferrin; Insulin-transferrin-selenium
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/30—Organic components
- C12N2500/32—Amino acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/30—Organic components
- C12N2500/36—Lipids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/90—Serum-free medium, which may still contain naturally-sourced components
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/155—Bone morphogenic proteins [BMP]; Osteogenins; Osteogenic factor; Bone inducing factor
Abstract
The invention discloses a kind of stem cell serum-free culture mediums, including basal medium, adding ingredient and combination of cytokines, using the volume of basal medium as benchmark, the additive composition and its content are respectively transferrins, volume ratio 5%-10%, insulin, 5-15mg/L, L-Glutamine, 2-4mM, growth factor, 5-15ng/mL, BMP-5 antibody, 0.05-0.25ng/mL, composite of lipid, 2-4mM and microelement, 1-5mg/L.The present invention uses the ingredient of the animal sources such as serum-free, it excludes in serum containing there are many uncertain substance (such as different antigen, antibody, hormone and cell factors) for the survival rate of hematopoietic stem cell population and the interference of proliferation process, and then increase the quantity for being proliferated high-efficient and high activity candidate stem cell, the content of cell factor type used in hematopoietic stem cell population process and addition is adjusted simultaneously, and then improve candidate stem cell be proliferated in vitro in activity, to reduce the death rate of cell.
Description
Technical field
Invention is related to Stem cells cultured in vitro technical field, specially a kind of stem cell serum-free culture medium.
Background technique
Marrow hemopoietic stem cells and adult Transplantation of Peripheral Haemopoietic Stem Cells can treat neoplastic hematologic disorder (such as leukaemia, multiple
Property myeloma etc.), alpastic anemia, immunologic deficiency disease and genetic disease.In recent years, due to umbilical hemopoietic stem cell base
Plinth progress of research finds to contain the candidate stem cell more richer than marrow in bleeding of the umbilicus, grows amplification ability and compare derived from bone marrow
It is abundant and be easy to get, safe and simple, less generation viral transmission and graft versus host disease(GVH disease) when acquisition.In the past, bleeding of the umbilicus is useless
Gurry, and it is present, and navel blood stem cell can be saved by unbilical blood bank, increase a possibility that it is rationally utilized.
But navel blood stem cell is made full use of then to need to increase navel blood stem cell using more methods, it studies at present
It must at most be the amplification in vitro of navel blood stem cell, however human or animal's serum will be routinely added in amplification in vitro, and contain in serum
There are many uncertain substance (such as different antigen, antibody, hormone and cell factors), and it is intracorporal especially to pay attention to animal in recent years
Virus infection may carry certain animal virus in serum, this is with serum amplification in vitro stem cell for the potential of transplanting
Danger, and then the survival rate and proliferation process of cell are influenced, in addition, the increment of candidate stem cell is broken up, reaches maturity
Process is considerably complicated, and dependent on the adjusting of various Hemopoietic factors, the effect that wherein cell stimulation factor plays is extremely crucial, and phase
The composition and content for closing cell stimulation factor have certain influence for the amplification in vitro of candidate stem cell, for this purpose, we mention
A kind of stem cell serum-free culture medium is gone out.
Summary of the invention
Invention is designed to provide a kind of stem cell serum-free culture medium, to solve mentioned above in the background art ask
Topic.
To achieve the above object, invention provides the following technical solutions: a kind of stem cell serum-free culture medium, feature exist
In: using the volume of basal medium as benchmark, the adding ingredient composition and its content are respectively transferrins, and volume ratio is
5%-10%, insulin, 5-15mg/L, L-Glutamine, 2-4mM, growth factor, 5-15ng/mL, BMP-5 antibody, 0.05-
0.25ng/mL, composite of lipid, 2-4mM and microelement, 1-5mg/L.
Preferably, the basal medium uses DMEM basal medium.
Preferably, using the volume of DMEM basal medium as benchmark, the combination of cytokines composition and content point
Not are as follows: stem cell factor (SCF), 10-20ng/mL, granulocyte-macrophage colony stimutaing factor (GM-CSF), 5-
15ng/mL, interleukin Ⅲ (IL-3), 1-5ng/mL and interleukin-6 (IL-6) 1-15ng/mL.
Preferably, the DMEM basal medium is high glycoform DMEM basal medium, concentration of glucose 3000mg/L-
4500mg/L。
Preferably, the stem cell serum-free culture medium is suitable for umbilical hemopoietic stem cell and marrow hemopoietic stem cells etc.
The amplification in vitro culture of candidate stem cell.
Preferably, the DMEM basal medium and additive are mixed to prepare culture solution according to designated volume ratio or content.
Preferably, the cell connector addition time is that candidate stem cell is inoculated in after culture solution and thin in Hematopoietic Stem
It is gradually added in born of the same parents' amplification in vitro.
Preferably, the hematopoietic stem cell population period is 14d.
Compared with prior art, advantageous effect of the invention is:
1, this kind of stem cell serum-free culture medium with DMEM basal medium, is added using the ingredient of the animal sources such as serum-free
Addition point and combination of cytokines three parts composition, exclude in serum containing there are many uncertain substance (such as different antigen,
Antibody, hormone and cell factor etc.) for the survival rate of hematopoietic stem cell population and the interference of proliferation process, into
And increase the quantity for being proliferated high-efficient and high activity candidate stem cell, preferably it is applied to neoplastic hematologic disorder (such as leukaemia, more
Hair property myeloma etc.), alpastic anemia, in immunologic deficiency disease and genetic disease.
2, this kind of stem cell serum-free culture medium, adjustment cell factor is used in the hematopoietic stem cell population process
Type and the content of addition, so improve candidate stem cell be proliferated in vitro in activity, to reduce the death rate of cell, into
And cell quantity is obviously increased in shorter cultivation cycle, while the culture medium can be suitable for simultaneously umbilical hemopoietic dry thin
The in-vitro multiplication and application of born of the same parents and marrow hemopoietic stem cells.
Specific embodiment
The technical scheme in the embodiments of the invention will be clearly and completely described below, it is clear that described implementation
Example is only a part of the embodiment of the present invention, instead of all the embodiments.Based on the embodiments of the present invention, this field is common
Technical staff's every other embodiment obtained without making creative work belongs to the model that the present invention protects
It encloses.
Embodiment one:
Invention provides a kind of technical solution: a kind of stem cell serum-free culture medium, it is characterised in that: be with concentration of glucose
For the volume of the high glycoform DMEM basal medium of 3750mg/L as benchmark, the adding ingredient composition and its content are respectively to turn
Ferritin, volume ratio 7.5%, insulin, 10mg/L, L-Glutamine, 3mM, growth factor, 10ng/mL, BMP-5 antibody,
0.15ng/mL, composite of lipid, 3mM and microelement, 3mg/L, meanwhile, the combination of cytokines composition and content
It is respectively as follows: stem cell factor (SCF), 15ng/mL, granulocyte-macrophage colony stimutaing factor (GM-CSF), 10ng/
ML, interleukin Ⅲ (IL-3), 3ng/mL and interleukin-6 (IL-6) 8ng/mL, the DMEM basal medium and add
Add agent to be mixed to prepare culture solution according to designated volume ratio or content, in 14d, by cell connector according to stem cell growth
The factor (SCF), interleukin Ⅲ (IL-3), interleukin-6 (IL-6) and granulocyte-macrophage colony stimutaing factor
(GM-CSF) sequence is added in culture solution, and the stem cell serum-free culture medium is suitable for umbilical hemopoietic stem cell and marrow
The amplification in vitro culture of the candidate stem cells such as candidate stem cell.
Embodiment two:
Invention provides a kind of technical solution: a kind of stem cell serum-free culture medium, it is characterised in that: be with concentration of glucose
For the volume of the high glycoform DMEM basal medium of 4500mg/L as benchmark, the adding ingredient composition and its content are respectively to turn
Ferritin, volume ratio 10%, insulin, 15mg/L, L-Glutamine, 4mM, growth factor, 5ng/mL, BMP-5 antibody,
0.25ng/mL, composite of lipid, 4mM and microelement, 5mg/L, meanwhile, the combination of cytokines composition and content
It is respectively as follows: stem cell factor (SCF), 20ng/mL, granulocyte-macrophage colony stimutaing factor (GM-CSF), 15ng/
ML, interleukin Ⅲ (IL-3), 5ng/mL and interleukin-6 (IL-6) 15ng/mL, the DMEM basal medium and
Additive is mixed to prepare culture solution according to designated volume ratio or content, will be raw according to stem cell in cell connector in 14d
The long factor (SCF), interleukin Ⅲ (IL-3), interleukin-6 (IL-6) and granulocyte-macrophage colony stimulation because
The sequence of sub (GM-CSF) is added in culture solution, and the stem cell serum-free culture medium is suitable for umbilical hemopoietic stem cell and bone
The amplification in vitro culture of the candidate stem cells such as marrow candidate stem cell.
Embodiment three: a kind of stem cell serum-free culture medium, it is characterised in that: with concentration of glucose be the height of 3000mg/L
For the volume of sugar-type DMEM basal medium as benchmark, the adding ingredient composition and its content are respectively transferrins, volume
Than for 5%, insulin, 5mg/L, L-Glutamine, 2mM, growth factor, 5ng/mL, BMP-5 antibody, 0.05ng/mL, lipid
Compound, 2mM and microelement, 1mg/L, meanwhile, the combination of cytokines composition and content are respectively as follows: stem cell life
The long factor (SCF), 10ng/mL, granulocyte-macrophage colony stimutaing factor (GM-CSF), 5ng/mL, interleukin Ⅲ
(IL-3), 1ng/mL and interleukin-6 (IL-6) 1ng/mL, the DMEM basal medium and additive are according to particular volume
Product ratio or content are mixed to prepare culture solution, in 14d, by cell connector according to stem cell factor (SCF), white thin
The sequence of born of the same parents' interleukin 3 (IL-3), interleukin-6 (IL-6) and granulocyte-macrophage colony stimutaing factor (GM-CSF)
It is added in culture solution, the stem cell serum-free culture medium is suitable for umbilical hemopoietic stem cell and marrow hemopoietic stem cells etc. and makes
The amplification in vitro culture of hemocytoblast.
Obviously, various changes and modifications can be made to the invention without departing from essence of the invention by those skilled in the art
Mind and range.In this way, if these modifications and changes of the present invention belongs to the range of the claims in the present invention and its equivalent technologies
Within, then the present invention is also intended to include these modifications and variations.
Claims (8)
1. a kind of stem cell serum-free culture medium, including basal medium, adding ingredient and combination of cytokines, feature exist
In: using the volume of basal medium as benchmark, the adding ingredient composition and its content are respectively transferrins, and volume ratio is
5%-10%, insulin, 5-15mg/L, L-Glutamine, 2-4mM, growth factor, 5-15ng/mL, BMP-5 antibody, 0.05-
0.25ng/mL, composite of lipid, 2-4mM and microelement, 1-5mg/L.
2. a kind of stem cell serum-free culture medium as described in claim 1, it is characterised in that: the basal medium uses
DMEM basal medium.
3. a kind of stem cell serum-free culture medium as claimed in claim 1 or 2, it is characterised in that: with DMEM basal medium
Volume as benchmark, the combination of cytokines composition and content are respectively as follows: stem cell factor (SCF), 10-
20ng/mL, granulocyte-macrophage colony stimutaing factor (GM-CSF), 5-15ng/mL, interleukin Ⅲ (IL-3), 1-
5ng/mL and interleukin-6 (IL-6) 1-15ng/mL.
4. a kind of stem cell serum-free culture medium as claimed in claim 2, it is characterised in that: the DMEM basal medium is
High glycoform DMEM basal medium, concentration of glucose 3000mg/L-4500mg/L.
5. a kind of stem cell serum-free culture medium as described in claim 1, it is characterised in that: the stem cell serum-free culture
Base is suitable for the amplification in vitro culture of the candidate stem cells such as umbilical hemopoietic stem cell and marrow hemopoietic stem cells.
6. a kind of stem cell serum-free culture medium as claimed in claim 1 or 2, it is characterised in that: the basis the DMEM culture
Base and additive are mixed to prepare culture solution according to designated volume ratio or content.
7. such as claim 3 or 6 or a kind of stem cell serum-free culture medium, it is characterised in that: the cell combination because
The son addition time is that candidate stem cell is inoculated in after culture solution and gradually adds in hematopoietic stem cell population.
8. such as claim 7 or a kind of stem cell serum-free culture medium, it is characterised in that: the candidate stem cell is external
The amplification period is 14d.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201811639110.7A CN109593717A (en) | 2018-12-29 | 2018-12-29 | A kind of stem cell serum-free culture medium |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201811639110.7A CN109593717A (en) | 2018-12-29 | 2018-12-29 | A kind of stem cell serum-free culture medium |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN109593717A true CN109593717A (en) | 2019-04-09 |
Family
ID=65965540
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201811639110.7A Pending CN109593717A (en) | 2018-12-29 | 2018-12-29 | A kind of stem cell serum-free culture medium |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN109593717A (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111117966A (en) * | 2020-03-02 | 2020-05-08 | 南通大学 | In-vitro cell culture method using lactic acid |
| CN112704729A (en) * | 2020-12-28 | 2021-04-27 | 江苏纳迪芯生命科技研究院有限公司 | Cytokine particle |
| CN113881633A (en) * | 2021-12-06 | 2022-01-04 | 山东省齐鲁干细胞工程有限公司 | Culture medium and method for in-vitro dry amplification of umbilical cord blood hematopoietic stem cells |
| CN116836920A (en) * | 2023-08-21 | 2023-10-03 | 佛山市生物医学工程学会 | Serum-free culture medium and method for preparing mesenchymal stem cells by using same |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5945337A (en) * | 1996-10-18 | 1999-08-31 | Quality Biological, Inc. | Method for culturing CD34+ cells in a serum-free medium |
| US20050032122A1 (en) * | 2003-08-06 | 2005-02-10 | Shiaw-Min Hwang | Optimizing culture medium for CD34<+> hematopoietic cell expansion |
| CN102827810A (en) * | 2012-09-19 | 2012-12-19 | 北京京蒙高科干细胞技术有限公司 | Non-animal-source serum-free culture medium for umbilical cord blood stem cells |
| CN105713880A (en) * | 2016-04-20 | 2016-06-29 | 广东艾时代生物科技有限责任公司 | Serum-free culture medium for hematopoietic stem cell in vitro expansion culture and application thereof |
| CN105838675A (en) * | 2016-06-07 | 2016-08-10 | 广东万海细胞生物科技有限公司 | Hematopoietic stem cell serum-free culture medium |
| US20180163177A1 (en) * | 2016-12-11 | 2018-06-14 | Healthbanks Biotech Co. Ltd. | Serum-free culture medium and method for expanding hematopoietic stem cells |
-
2018
- 2018-12-29 CN CN201811639110.7A patent/CN109593717A/en active Pending
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5945337A (en) * | 1996-10-18 | 1999-08-31 | Quality Biological, Inc. | Method for culturing CD34+ cells in a serum-free medium |
| US20050032122A1 (en) * | 2003-08-06 | 2005-02-10 | Shiaw-Min Hwang | Optimizing culture medium for CD34<+> hematopoietic cell expansion |
| CN102827810A (en) * | 2012-09-19 | 2012-12-19 | 北京京蒙高科干细胞技术有限公司 | Non-animal-source serum-free culture medium for umbilical cord blood stem cells |
| CN105713880A (en) * | 2016-04-20 | 2016-06-29 | 广东艾时代生物科技有限责任公司 | Serum-free culture medium for hematopoietic stem cell in vitro expansion culture and application thereof |
| CN105838675A (en) * | 2016-06-07 | 2016-08-10 | 广东万海细胞生物科技有限公司 | Hematopoietic stem cell serum-free culture medium |
| US20180163177A1 (en) * | 2016-12-11 | 2018-06-14 | Healthbanks Biotech Co. Ltd. | Serum-free culture medium and method for expanding hematopoietic stem cells |
Non-Patent Citations (4)
| Title |
|---|
| DETMER K 等: "Bone morphogenetic proteins act synergistically with haematopoietic cytokines in the differentiation of haematopoietic progenitors", 《CYTOKINE》 * |
| JUNG S 等: "Ex vivo expansion of human mesenchymal stem cells in defined serum-free media", 《STEM CELLS INTERNATIONAL》 * |
| 张学娟 等: "无血清和有血清培养人脐带间充质干细胞的对比", 《中国组织工程研究》 * |
| 阿尔祖古丽 等: "动物细胞无血清培养技术研究进展", 《甘肃畜牧兽医》 * |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111117966A (en) * | 2020-03-02 | 2020-05-08 | 南通大学 | In-vitro cell culture method using lactic acid |
| CN112704729A (en) * | 2020-12-28 | 2021-04-27 | 江苏纳迪芯生命科技研究院有限公司 | Cytokine particle |
| CN113881633A (en) * | 2021-12-06 | 2022-01-04 | 山东省齐鲁干细胞工程有限公司 | Culture medium and method for in-vitro dry amplification of umbilical cord blood hematopoietic stem cells |
| CN113881633B (en) * | 2021-12-06 | 2022-02-22 | 山东省齐鲁干细胞工程有限公司 | Culture medium and method for in-vitro dry amplification of umbilical cord blood hematopoietic stem cells |
| CN116836920A (en) * | 2023-08-21 | 2023-10-03 | 佛山市生物医学工程学会 | Serum-free culture medium and method for preparing mesenchymal stem cells by using same |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN109593717A (en) | A kind of stem cell serum-free culture medium | |
| Lachmann et al. | Large-scale hematopoietic differentiation of human induced pluripotent stem cells provides granulocytes or macrophages for cell replacement therapies | |
| Koller et al. | Tissue engineering: reconstitution of human hematopoiesis ex vivo | |
| CN101864396B (en) | Method for inducing megakaryoblast and megakaryocyte in vitro | |
| KR102292843B1 (en) | Induced pluripotent stem cell(iPSC) derived natural killer cell and its use | |
| Wolf et al. | Development of a bone marrow culture for maintenance and growth of normal human B cell precursors. | |
| EP2142642B1 (en) | Methods and means for stem cell proliferation and subsequent generation and expansion of progenitor cells, as well as production of effector cells as clinical therapeutics | |
| JP2019150040A (en) | Enriched and expanded human cord blood stem cells for treatment of hematological disorders | |
| Silva et al. | Toward personalized cell therapies by using stem cells: seven relevant topics for safety and success in stem cell therapy | |
| US20110217263A1 (en) | Expansion of haemopoietic precursors | |
| CN104988110A (en) | Method for transforming umbilical cord mesenchymal stem cells into islet cells | |
| CN102465112A (en) | Human umbilical cord blood hematopoietic stem cell high-efficiency in vitro amplification technology | |
| CN103255103A (en) | Serum-free adipose tissue-derived mesenchymal stem cell culture medium | |
| US8168429B2 (en) | Method of amplifying hematopoietic stem cell and hematopoietic progenitor cell | |
| CN103740644A (en) | Method for amplifying hematopoietic stem cells based on 3D culture system | |
| Panuganti et al. | Bone marrow niche-inspired, multiphase expansion of megakaryocytic progenitors with high polyploidization potential | |
| Pochon et al. | Wharton’s jelly‐derived stromal cells and their cell therapy applications in allogeneic haematopoietic stem cell transplantation | |
| Ghaffari et al. | Impact of various culture conditions on ex vivo expansion of polyclonal T cells for adoptive immunotherapy | |
| CN105316293A (en) | Method for obtaining hematopoietic stem cells/hematopoietic progenitor cells in vitro | |
| US5468635A (en) | In vitro method for stimulating cell growth by culturing cells in a serum-free culture medium comprising human lysozyme | |
| CN110551688A (en) | Composition for inducing reprogramming of somatic cells into hematopoietic stem/progenitor cells and promoting in-vitro expansion of hematopoietic stem/progenitor cells and application thereof | |
| Kim et al. | Ex vivo expansion and clonality of CD34+ selected cells from bone marrow and cord blood in a serum-free media | |
| CN109777771A (en) | The serum free medium and its application method of primary umbilical cord mesenchymal stem cells | |
| CN113005082B (en) | T cell serum-free culture medium and application thereof | |
| Xiong et al. | Ex vivo expansion of human umbilical cord blood hematopoietic progenitor cells in a novel three-dimensional culture system |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20190409 |